Evidence summaries and landmark trials across type 1, type 2, prevention, glycaemic control, complications, and diabetes technology.
A model-based analysis of a 28-week randomized meal-test substudy comparing tirzepatide 15 mg with semaglutide 1 mg in metformin-treated type 2 diabetes. PICO summary and expert commentary.
Prespecified FLOW subgroup analysis testing whether semaglutide's kidney and cardiovascular benefits hold with or without baseline SGLT2 inhibitor use. PICO summary and expert commentary.
An exploratory imaging substudy of a 32-week randomised trial finds semaglutide and empagliflozin each lower cortical apparent diffusion coefficient and reduce total kidney volume in type 2 diabetes. PICO summary and expert commentary.
PIONEER 11 found that oral semaglutide monotherapy lowered HbA1c at all doses versus placebo in drug-naive, predominantly Chinese adults with type 2 diabetes, with weight reduction confined to the 7 mg and 14 mg doses. PICO summary and expert commentary.
Prespecified FLOW secondary analysis testing whether semaglutide's kidney and cardiovascular benefit differs by baseline SGLT2 inhibitor use in type 2 diabetes with chronic kidney disease. PICO summary and expert commentary.
Pre-specified FLOW subgroup analysis of semaglutide for kidney outcomes in type 2 diabetes and chronic kidney disease, by baseline SGLT2 inhibitor use. PICO summary and expert commentary.
In the FLOW trial, once-weekly semaglutide 1.0 mg lowered the risk of major kidney disease events and death from cardiovascular causes in patients with type 2 diabetes and chronic kidney disease. PICO summary and expert commentary.
In adults with diabetes mellitus but no evident cardiovascular disease, aspirin at a dose of 100 mg daily significantly reduced the risk of serious vascular events by 12% compared to placebo, though it was associated with a 29% increased risk of major bleeding events.
Welcome to Hormone Insight. Our mission is to support clinical decision-making with accessible, evidence-based insights from recent studies and trials.
© 2024-2026 Hormone Insight. All rights reserved.
